BRK”ing” Down All We Know About PTK6 in Breast Cancer

Yi Yuan,Hui Li Ang,Xianning Lai,Lingzhi Wang,Vijay Pandey,Benjamin BoJun Huang,Tuan Zea Tan,Hui Yi Chong,Philip Zheng Yang Ong,Kanchugarakoppal S. Rangappa,Frank Arfuso,Kevin Shyong-Wei Tan, Basappa,Boon Cher Goh,Ruby Yun-Ju Huang,Gautam Sethi,Peter E. Lobie,Alan Prem Kumar
DOI: https://doi.org/10.20944/preprints201808.0044.v1
2018-01-01
Abstract:The search for improved therapeutic approaches to breast cancer are still on going. Breast tumor kinase (BRK, also known as PTK6) is one of the targets, it is highly expressed in breast carcinomas while displaying low or no expression in the normal mammary gland, which hints at the oncogenic role of this enzyme in breast cancer. In these twenty years, an increasing number of studies have focused on understanding the cellular roles of BRK in breast cancers. This review outlines the advances made towards understanding the cellular and physiological role of BRK, the molecular and chemical inhibitors and its therapeutic significance in breast cancer.
What problem does this paper attempt to address?